3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Solid Tumors
1
Recurrence
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Advanced Solid Tumors
1
Interventions
Dexamethasone
129
Lenalidomide
70
Cyclophosphamide
70
Bortezomib
69
Calcium Dobesilate
50
fludarabine
44
pomalidomide
40
daratumumab
37
carfilzomib
33
fludarabine phosphate
31
Melphalan
25
dexamethasone acetate
20
dexamethasone 21-phosphate
20
auricularum
18
Filgrastim
18
Whole-Body Irradiation
14
Biopsy
13
isatuximab
12
Vorinostat
12
Tacrolimus
12
Peripheral Blood Stem Cell Transplantation
12
Magnetic Resonance Spectroscopy
12
Granulocyte Colony-Stimulating Factor
12
Specimen Handling
11
Sirolimus
11
ixazomib
10
belantamab mafodotin
10
Panobinostat
10
Mycophenolic Acid
10
Cyclosporine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Multiple Myeloma
×
Dosage Forms
×
Clear all
NCT02939183
2024-09-26
INTREPID-1
Amgen
Phase 1
Completed
61 enrolled
28 charts